Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260443 | 0.92 | SMYD3 (0.39) | SMYD3EPHX2ARKMT2AMEN1 | |
| SCHEMBL621055 | 0.92 | SMYD3 (0.39) | SMYD3EPHX2ARKMT2AMEN1 | |
| SCHEMBL17740909 | 0.91 | SMYD3 (0.37) | SMYD3EPHX2ARKMT2AMEN1 | |
| SCHEMBL17740911 | 0.89 | SMYD3 (0.38) | SMYD3EPHX2ARKMT2AMEN1 | |
| SCHEMBL17740919 | 0.88 | SMYD3 (0.39) | SMYD3EPHX2ARKMT2AMEN1 | |
| SCHEMBL17740878 | 0.85 | SMYD3 (0.45) | SMYD3EPHX2KMT2AMEN1LDHA | |
| SCHEMBL17740893 | 0.84 | SMYD3 (0.46) | SMYD3EPHX2KMT2AMEN1LDHA | |
| SCHEMBL17740879 | 0.84 | SMYD3 (0.48) | SMYD3EPHX2KMT2AMEN1LDHA | |
| SCHEMBL17740898 | 0.84 | SMYD3 (0.42) | SMYD3EPHX2KMT2AMEN1LDHA | |
| SCHEMBL17740908 | 0.84 | SMYD3 (0.38) | SMYD3EPHX2ARKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065302-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED | 2024-02-29 | — | — | US | disclosed |
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | FIRMENICH INCORPORATED (US) | 2022-05-24 | — | — | US | disclosed |
| US-20180086751-A1 | SWEETENER COMPOSITION | SENOMYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160185727-A1 | SUBSTITUTED 4-AMINO-5-(CYCLOHEXYLOXY)QUINOLINE-3-CARBOXYLIC ACIDS AS SWEET FLAVOR MODIFIERS | FIRMENICH INCORPORATED | 2016-06-30 | — | — | US | disclosed |
| WO-2016073251-A1 | SUBSTITUTED 4-AMINO-5-(CYCLOHEXYLOXY)QUINOLINE-3-CARBOXYLIC ACIDS AS SWEET FLAVOR MODIFIERS | SENOMYX, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | TAS2R5, TAS2R4, TAS2R30 | SMYD3 1526/4885EPHX2 4445/4885AR 4692/4885 |
| US-20180086751-A1 | SWEETENER COMPOSITION | TAS2R50, TAS1R2, TAS2R10 | SMYD3 297/4885EPHX2 4039/4885AR 4543/4885 |
| US-20160185727-A1 | SUBSTITUTED 4-AMINO-5-(CYCLOHEXYLOXY)QUINOLINE-3-CARBOXYLIC ACIDS AS SWEET FLAVOR MODIFIERS | TAS2R5, TAS2R4, TAS2R30 | SMYD3 1526/4885EPHX2 4445/4885AR 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.